Anti-inflammatory cytokine adiponectin in relation to glucose concentration in type II diabetes men

Paper Details

Research Paper 01/01/2014
Views (157) Download (7)

Anti-inflammatory cytokine adiponectin in relation to glucose concentration in type II diabetes men

Kaboli Mohamadzaman, Ferizadeh Abbas, Maleki Behnam, Ghazaei Anbaran Yavar
J. Bio. Env. Sci.4( 1), 244-249, January 2014.
Certificate: JBES 2014 [Generate Certificate]


Adiponectin, a hormone secreted by adipose tissue, plays an important role in the genesis of obesity and type II diabetes. The purpose of this study was to compare adiponectin between type II diabetes and non-diabetes men and to examine the relation of serum adiponectin to glucose concentration in type II diabetic patients. Sedentary adult men with type II diabetes (n=12) or non-diabetes (n=12) men were recruited and underwent testing for measurement of body mass index, body composition and blood levels of adiponectin, insulin and glucose. Fasting blood samples were collected from brachial vein in sitting position of all participants in two groups. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was calculated by fasting insulin and glucose. Serum insulin levels in patients with diabetic showed were significantly higher than those without diabetes symptoms (p = 0.018). Insulin resistance and fasting glucose was also higher in patients than non-diabetes subjects (p = 0.000). There were no significant correlations between serum adiponectin concentrations and fasting glucose in patients (p = 0.38, r = 0.28). Also this anti-inflammatory cytokine was not related to insulin resistance in patients (p = 0.64, r = 0.15). Despite higher serum adiponectin in diabetic patients, but this cytokine can not affect circulation glucose directly.


Aldhahi W, Hamdy O. 2003. Adipokines, inflammation, and the endothelium in diabetes. Current Diabetes Reports 3(4), 293-8.

Calabro P, Yeh ET. 2007. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Sub-cellular biochemistry 42, 63-91.

Choi KM. 2004. The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. European Journal of Endocrinology 150(5), 715-8.

Courteix D, Rieth N, Thomas T, Van Praagh E, Benhamou CL, Collomp K. 2007. Preserved bone health in adolescent elite rhythmic gymnasts despite hypoleptinemia. Hormone Research 68(1), 20-7.

Hadaegh F, Harati H, Ghanbarian A, Azizi F. 2006. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. European Journal of Cardiovascular Prevention & Rehabilitation 13, 571-577.

Harsch IA, Koebnick C, Tasi AM, Hahn EG, Konturek PC. 2009. Ghrelin and Obestatin Levels in Type 2 Diabetic Patients With and Without Delayed Gastric Emptying. Digestive Diseases and Sciences 54(10), 2161-6.

Hersoug LG, Linneberg A. 2007. The link between the epidemics of obesity and allergic diseases: does obesity induce decreased immune tolerance? Allergy 62(10), 1205-13.

Kahn SE. 2003. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46, 3–19.

Katsuki A, Urakawa H, Gabazza EC, Murashima S, Nakatani K, Togashi K. 2004.Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. European Journal of Endocrinology 151(5), 573-7.

Kondo T, Kobayashi I, Murakami M. 2006. Effect of exercise on circulating adipokine levels in obese young women. Endocrine Journal 53(2), 189-95.

Ma K, Cabrero A, Saha P, Kojima H, Li L, Hing-Junn B, Paul A, Chan L. 2002. Increased b-oxidation but no insulin resistance on glucose intolerance in mice lacking adiponectin. Journal of Biological Chemistry 277, 34658–34661.

Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8, 731–737.

Martin M, Palaniappan LP, Kwan AC, Reaven G. 2008. Ethnic differences in the relationship between adiponectin and in- sulin sensitivity in South Asian and Cau- casian women. Diabetes Care 31, 798-801.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7), 412-419.

Moreno-Aliaga MJ, Lorente-Cebrián S, Martínez JA. 2010. Regulation of adipokine secretion by n-3 fatty acids. Proceedings of the Nutrition Society 69(3), 324-32.

Pischon T, Rimm EB. 2006. Adiponectin: a promising marker for cardiovascular disease. Clinical Chemistry 52, 797–799.

Pulkkinen L, Ukkola O, Kolehmainen M, Uusitupa M. 2010. Ghrelin in Diabetes andMetabolic Syndrome. International Journal of Peptide 24, 4-8.

Ryan AS, Berman DM, Nicklas BJ, Sinha MS, Gingerich RL, Meneilly GS, Egan JM, Elahi D. 2003. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 26, 2383- 2388.

Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, HaringH, Stumvoll M. 2003. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 239–243.

Ueno H, Shiiya T, Mizuta M, Mondal SM, Nakazato M. 2007. Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocrine Journal 54(6), 895-902.